HanAll Biopharma, Restructured to Seung-kook Park and Seung-won Jeong Joint Representative System, Accelerating Advancement as a Global Biopharmaceutical Company
HanAll Biopharma, Restructured to Seung-kook Park and Seung-won Jeong Joint Representative System, A..
HanAll Biopharma’s Chinese Partner HBM Initiates the First Dosing of Phase 3 in Dry Eye Disease
HanAll Biopharma’s Chinese Partner HBM Initiates the First Dosing of Phase 3 in Dry Eye Disease
HanAll Biopharma Completes Meeting with FDA for next Phase 3 Trials in Dye Eye Disease
HanAll Biopharma Completes Meeting with FDA for next Phase 3 Trials in Dye Eye Disease
HanAll Biopharma Net Income for 2020 Increased by 14% Year-on-year to KRW 21.9 Billion
HanAll Biopharma Net Income for 2020 Increased by 14% Year-on-year to KRW 21.9 Billion
HanAll Biopharma HL036 Clinical Trial Results Selected as Best Poster at AAO 2020
HanAll Biopharma HL036 Clinical Trial Results Selected as Best Poster at AAO 2020
HanAll Biopharma Recorded KRW 22.1 Billion, KRW 1 Billion, and KRW 3.7 Billion in Sales, Operating Income, and Net Profit for the Third Quarter
HanAll Biopharma Recorded KRW 22.1 Billion, KRW 1 Billion, and KRW 3.7 Billion in Sales, Operating I..